Overview

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Status:
Enrolling by invitation
Trial end date:
2033-06-01
Target enrollment:
Participant gender:
Summary
This is a long-term follow up study evaluating the safety of BPX-501 T cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bellicum Pharmaceuticals